| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marina Sokolenko, Stan Kutche. Sertraline for social anxiety disorder. Expert review of neurotherapeutics. vol 3. issue 6. 2010-06-28. PMID:19810881. |
selective serotonin reuptake inhibitors have been widely used for the treatment of anxiety disorders, with more data currently available for paroxetine. |
2010-06-28 |
2023-08-12 |
Not clear |
| D M Glubb, P C McHugh, X Deng, P R Joyce, M A Kenned. Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine. The pharmacogenomics journal. vol 10. issue 2. 2010-06-14. PMID:19636336. |
to identify genes that may be relevant to the molecular action of antidepressants, we investigated transcriptional changes induced by the selective serotonin reuptake inhibitor paroxetine in a serotonergic cell line. |
2010-06-14 |
2023-08-12 |
Not clear |
| Hugo R Arias, Dominik Feuerbach, Pankaj Bhumireddy, Marcelo O Ortell. Inhibitory mechanisms and binding site location for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors. The international journal of biochemistry & cell biology. vol 42. issue 5. 2010-06-11. PMID:20079457. |
functional and structural approaches were used to examine the inhibitory mechanisms and binding site location for fluoxetine and paroxetine, two serotonin selective reuptake inhibitors, on nicotinic acetylcholine receptors (achrs) in different conformational states. |
2010-06-11 |
2023-08-12 |
Not clear |
| Eun-Ho Kang, Hyun-Bo Shim, Kyung-Jeong Kim, Joo-Eon Park, In-Soo Lee, Bum-Hee Y. Platelet serotonin transporter function after short-term paroxetine treatment in patients with panic disorder. Psychiatry research. vol 176. issue 2-3. 2010-05-14. PMID:20207008. |
platelet serotonin transporter function after short-term paroxetine treatment in patients with panic disorder. |
2010-05-14 |
2023-08-12 |
human |
| Eduardo A Schilman, Oded Klavir, Christine Winter, Reinhard Sohr, Daphna Joe. The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 4. 2010-04-28. PMID:20072118. |
we have recently found that lesions to the rat orbitofrontal cortex (ofc) led to an increase in compulsive lever-pressing that was prevented by systemic administration of the selective serotonin reuptake inhibitor paroxetine, and paralleled by an increase in the density of the striatal serotonin transporter. |
2010-04-28 |
2023-08-12 |
rat |
| Roberto Casell. [Therapy for male patients with sexual dysfunction]. Therapeutische Umschau. Revue therapeutique. vol 67. issue 3. 2010-04-23. PMID:20235039. |
topical therapy with lidocaine/prilocaine-containing medications to be applied before sexual intercourse and a oral daily off label use therapy with selective serotonin re-uptake inhibitors (paroxetine, fluoxetine, sertraline) can be offered. |
2010-04-23 |
2023-08-12 |
Not clear |
| Carol A Pamer, Tarek A Hammad, Yu-Te Wu, Sigal Kaplan, George Rochester, Laura Governale, Andrew D Mosholde. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiology and drug safety. vol 19. issue 2. 2010-04-19. PMID:20049836. |
to determine if paroxetine versus non-paroxetine selective serotonin reuptake inhibitors (ssris) prescribing changed after the june 2003 fda paroxetine public health advisory (ppha) and if antidepressant and antipsychotic prescribing changed after the february 2004 fda advisory committee meeting (fdacm). |
2010-04-19 |
2023-08-12 |
Not clear |
| Alessandra Cubeddu, Andrea Giannini, Fiorella Bucci, Sara Merlini, Elena Casarosa, Nicola Pluchino, Stefano Luisi, Michele Luisi, Andrea R Genazzan. Paroxetine increases brain-derived neurotrophic factor in postmenopausal women. Menopause (New York, N.Y.). vol 17. issue 2. 2010-04-16. PMID:19934779. |
moreover, because endogenous gonadal hormones modulate both bdnf expression and serotonin biosynthesis and bioavailability and regulate brain functions like affective and cognitive functions, we proposed to evaluate the effects of a treatment with paroxetine, an ssri, in a group of postmenopausal women and to clarify the possible relationship between paroxetine, plasma bdnf levels, and climacteric symptoms. |
2010-04-16 |
2023-08-12 |
Not clear |
| A L Montejo, N Prieto, A Terleira, J Matias, S Alonso, G Paniagua, S Naval, D G Parra, C Gabriel, E Mocaër, A Portolé. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of psychopharmacology (Oxford, England). vol 24. issue 1. 2010-04-15. PMID:18801825. |
sexual acceptability of agomelatine (a melatonergic agonist and 5ht(2c) antagonist) paroxetine and placebo by using the psychotropic-related sexual dysfunction salamanca sex questionnaire (prsexdq-salsex) was explored. |
2010-04-15 |
2023-08-12 |
human |
| Jo Unotoro, Eishin Nonaka, Naohito Takita, Yoshimasa Suzuk. [Paroxetine treatment of 3 cases of cholestatic pruritus due to gastrointestinal malignancy]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. vol 107. issue 2. 2010-04-15. PMID:20134129. |
recently, the antipruritic activity of the selective serotonin reuptake inhibitor paroxetine has been reported. |
2010-04-15 |
2023-08-12 |
Not clear |
| Francesco Cresp. The selective serotonin reuptake inhibitor fluoxetine reduces striatal in vivo levels of voltammetric nitric oxide (NO): a feature of its antidepressant activity? Neuroscience letters. vol 470. issue 2. 2010-04-06. PMID:20036714. |
preliminary in vitro studies have shown that the selective serotonin reuptake inhibitor (ssri) antidepressant paroxetine inhibits constitutive nitric oxide synthase (cnos) activity in animals and humans and that another ssri such as fluoxetine reduced no release in the media of synovial cells. |
2010-04-06 |
2023-08-12 |
rat |
| Yusuke Murata, Daisuke Kobayashi, Nanae Imuta, Koichi Haraguchi, Ichiro Ieiri, Ryoji Nishimura, Susumu Koyama, Kazunori Min. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. Journal of clinical psychopharmacology. vol 30. issue 1. 2010-03-19. PMID:20075642. |
effects of the serotonin 1a, 2a, 2c, 3a, and 3b and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. |
2010-03-19 |
2023-08-12 |
Not clear |
| Yusuke Murata, Daisuke Kobayashi, Nanae Imuta, Koichi Haraguchi, Ichiro Ieiri, Ryoji Nishimura, Susumu Koyama, Kazunori Min. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. Journal of clinical psychopharmacology. vol 30. issue 1. 2010-03-19. PMID:20075642. |
in this study, we investigated the effects of genetic polymorphisms in the serotonin 1a, 2a, 2c, 3a, and 3b receptor, the serotonin transporter, and the cytochrome p450 2d6 (cyp2d6) genes on the occurrence of paroxetine discontinuation syndrome. |
2010-03-19 |
2023-08-12 |
Not clear |
| Yusuke Murata, Daisuke Kobayashi, Nanae Imuta, Koichi Haraguchi, Ichiro Ieiri, Ryoji Nishimura, Susumu Koyama, Kazunori Min. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. Journal of clinical psychopharmacology. vol 30. issue 1. 2010-03-19. PMID:20075642. |
patients who had the -1019c allele experienced paroxetine discontinuation syndrome more frequently than patients who had the -1019g homozygote (nominal p = 0.0423) of the serotonin 1a receptor gene. |
2010-03-19 |
2023-08-12 |
Not clear |
| Yusuke Murata, Daisuke Kobayashi, Nanae Imuta, Koichi Haraguchi, Ichiro Ieiri, Ryoji Nishimura, Susumu Koyama, Kazunori Min. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. Journal of clinical psychopharmacology. vol 30. issue 1. 2010-03-19. PMID:20075642. |
the findings suggest that the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome and that c(-1019)g polymorphism of the serotonin 1a receptor gene may be related to the occurrence of the syndrome. |
2010-03-19 |
2023-08-12 |
Not clear |
| b' Kristof Demeestere, Mira Petrovi\\xc4\\x87, Meritxell Gros, Jo Dewulf, Herman Van Langenhove, Dami\\xc3\\xa0 Barcel\\xc3\\xb. Trace analysis of antidepressants in environmental waters by molecularly imprinted polymer-based solid-phase extraction followed by ultra-performance liquid chromatography coupled to triple quadrupole mass spectrometry. Analytical and bioanalytical chemistry. vol 396. issue 2. 2010-02-23. PMID:19924405.' |
a systematic optimization study revealed that, among the seven compounds of interest, mainly the selective serotonin reuptake inhibitors paroxetine, fluoxetine, and citalopram are selectively retained on the mips. |
2010-02-23 |
2023-08-12 |
Not clear |
| Charles H K West, James C Ritchie, Katherine A Boss-Williams, Jay M Weis. Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. The international journal of neuropsychopharmacology. vol 12. issue 5. 2010-02-12. PMID:18950545. |
to assess whether decreased lc activity is produced by drugs that selectively block reuptake for either norepinephrine or serotonin at therapeutically relevant blood levels, effects of chronic administration of desipramine, paroxetine, and escitalopram on lc activity were measured across a range of doses and blood levels of drug. |
2010-02-12 |
2023-08-12 |
Not clear |
| Patricia M Santos, Giselli Scaini, Gislaine T Rezin, Joana Benedet, Natália Rochi, Gabriela C Jeremias, Milena Carvalho-Silva, João Quevedo, Emilio L Strec. Brain creatine kinase activity is increased by chronic administration of paroxetine. Brain research bulletin. vol 80. issue 6. 2010-01-20. PMID:19772902. |
considering that ck plays an important role in brain energy homeostasis and that some antidepressants may modulate energy metabolism, we decided to investigate ck activity from rat brain after chronic administration of paroxetine (selective serotonin reuptake inhibitor), nortriptiline (tricyclic antidepressant) and venlafaxine (selective serotonin-norepinephrine reuptake inhibitor). |
2010-01-20 |
2023-08-12 |
rat |
| Agomelatine: new drug. Adverse effects and no proven efficacy. Prescrire international. vol 18. issue 104. 2010-01-12. PMID:20020562. |
(1) when an antidepressant is considered a necessary addition to psychological support in treating patients with depression, the first-line drug is a tricyclic such as clomipramine or a selective serotonin reuptake inhibitor (ssri) such as paroxetine; (2) agomelatine, a melatonin receptor agonist, is approved in the european union for the treatment of depression; (3) available evaluation does not include any clinical trials designed to compare the efficacy of agomelatine with that of a tricyclic or a selective serotonin reuptake inhibitor. |
2010-01-12 |
2023-08-12 |
Not clear |
| Ming-Ling Wu, Jou-Fang Den. Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline. Journal of the Chinese Medical Association : JCMA. vol 72. issue 8. 2009-12-09. PMID:19687003. |
moclobemide is a reversible inhibitor of monoamine oxidase (mao)-a, selegiline is an irreversible selective inhibitor of mao-b, and paroxetine is a selective serotonin reuptake inhibitor. |
2009-12-09 |
2023-08-12 |
Not clear |